Precision Surgery for Glioblastomas

Stephen J. Price, Jasmine G. Hughes, Swati Jain, Caroline Kelly, Ioana Sederias, Francesca M. Cozzi, Jawad Fares, Yonghao Li, Jasmine C. Kennedy, Roxanne Mayrand, Queenie Hoi Wing Wong, Yizhou Wan, Chao LiJournal of Personalized Medicine 2025 · OpenReview

TL;DR

Glioblastomas are aggressive brain tumors, and while surgery is crucial, current approaches lack personalization. This paper proposes a "precision surgery" framework, integrating personalized pre-operative preparation, refined surgical targeting using advanced imaging, and tailored post-operative rehabilitation to improve patient outcomes.

What Problem Does This Paper Address?

Glioblastomas are the most common and deadliest primary brain tumors. While surgical resection is a cornerstone of treatment, its effectiveness is limited by the tumor's infiltrative nature, making complete removal without causing significant neurological damage challenging. Current surgical practices, though often considered personalized, exhibit considerable variability between surgeons, highlighting a need for more objective, individualized approaches. The paper addresses the gap in personalized treatment strategies for glioblastomas by proposing a comprehensive framework that extends beyond the operating room to encompass pre-operative optimization and post-operative care.

Methods

The paper advocates for a personalized medicine approach to glioblastoma surgery, broken down into five key areas:

  • Patient Selection: Identifying patients who will benefit most from aggressive surgical approaches.
  • Pre-operative Optimization: This involves "prehabilitation," a process to improve a patient's physical and mental health before surgery. This includes objective assessment and screening for neurological deficits, and developing tailored interventions.
  • Individualized Resection Target: This is the core of "precision surgery." It involves:
  • What to Resect: Utilizing advanced imaging techniques like 5-ALA fluorescence, FET-PET, MR Spectroscopy, and Diffusion Tensor MRI (DTI) to better delineate the contrast-enhancing tumor and surrounding infiltrative tumor margins. The paper emphasizes moving beyond just the contrast-enhancing tumor to include non-enhancing tumor areas (FLAIR signal) where viable tumor cells exist.
  • What Not to Resect: Crucially, this involves understanding and mapping critical brain structures (motor, language, visual, and cognitive pathways) using fMRI and DTI tractography to avoid damaging them and preserve quality of life.
  • Personalized Rehabilitation: Tailoring post-operative rehabilitation plans to optimize recovery and adjuvant therapy.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Surgery is not as "personalized" as we think: The significant variability in resection extent among surgeons points to a need for more objective measures.
  • Beyond the Contrast-Enhancing Tumor: The paper argues for resecting beyond the visible contrast-enhancing tumor into the FLAIR signal area to improve outcomes, but this must be balanced with preserving critical brain function.
  • Prehabilitation is Key: For glioblastoma patients, who often have pre-existing deficits and a short window for adjuvant therapy, improving their functional status before surgery is critical.
  • Advanced Imaging is Essential for Targeting: Techniques like 5-ALA, FET-PET, DTI, and fMRI are vital for accurately identifying tumor margins and critical brain structures, enabling more precise surgical planning.
  • Connectomics for Cognition: Understanding cognitive function requires moving beyond simple anatomical models to considering complex neural networks (connectomes) and how tumors disrupt them.
  • Personalized Rehabilitation Matters: Even with limited survival, rehabilitation can significantly improve quality of life and community independence.

Key Results

The paper is a review and proposal, rather than a report of new experimental results. However, it synthesizes findings from numerous studies, highlighting:

  • Improved Survival with Gross Total Resection: Multiple studies confirm that achieving a gross total resection of the contrast-enhancing tumor improves survival and progression-free survival.
  • Supramaximal Resection Benefits: Resections extending into the non-enhancing tumor (FLAIR signal) have shown improved survival, with some studies suggesting a 6.4-month survival advantage.
  • 5-ALA Efficacy: 5-ALA fluorescence-guided resection has demonstrated significantly higher complete resection rates (65% vs. 29% in one trial) compared to white light resection.
  • DTI for Predicting Recurrence: Diffusion Tensor MRI shows promise in identifying areas of tumor invasion and predicting sites of recurrence.
  • Cognitive Deficits are Common: Glioblastoma patients often experience cognitive deficits before surgery, which can worsen post-operatively but typically improve before radiotherapy.
  • Rehabilitation Improves Outcomes: Evidence suggests that brain tumor patients can significantly improve function with rehabilitation, leading to better community independence and survival.

Limitations and Future Work

  • Defining "Supramaximal Resection": There's a lack of standardized definitions for supramaximal resection, making comparisons across studies difficult.
  • Translating Imaging to the OR: A significant challenge remains in effectively visualizing and translating 2D imaging data into the 3D intraoperative surgical field.
  • Prehabilitation Evidence Gap: While prehabilitation shows promise, specific evidence for its application in brain tumor patients is still limited.
  • Understanding Cognitive Reserve: Further research is needed to understand individual differences in resilience to cognitive decline and how network disruption relates to specific deficits.
  • Integrating SDM: More work is required to effectively incorporate prognostic information and tools into shared decision-making (SDM) processes.
  • Evidence for Rehabilitation: While promising, more research is needed on the effectiveness of specific rehabilitation interventions in neuro-oncology.
  • MGMT Methylation Status: Real-time intraoperative determination of MGMT methylation status is needed to tailor surgical goals based on predicted response to chemotherapy.

Summary updated

Abstract

Glioblastomas are the most common primary malignant brain tumor. Most of the recent improvements their treatment are due to improvements in surgery. Although many would consider surgery as the most personalized treatment, the variation in resection between surgeons suggests there remains a need for objective measures to determine the best surgical treatment for individualizing therapy for glioblastoma. We propose applying a personalized medicine approach to improve outcomes for patients. We suggest looking at personalizing preoperative preparation, improving the resection target by understanding what needs removing and what ca not be removed, and better patient selection with personalized rehabilitation plans for all patients.
BibTeX
@article{price2025precision,
  author = {Stephen J. Price and Jasmine G. Hughes and Swati Jain and Caroline Kelly and Ioana Sederias and Francesca M. Cozzi and Jawad Fares and Yonghao Li and Jasmine C. Kennedy and Roxanne Mayrand and Queenie Hoi Wing Wong and Yizhou Wan and Chao Li},
  title = {{Precision Surgery for Glioblastomas}},
  journal = {Journal of Personalized Medicine},
  year = {2025},
  url = {https://openreview.net/forum?id=CGyEhEGadh},
}
Figure